In a recent study titled “BRAF V600 mutations and pathological features in Japanese melanoma patients”, published in Melanoma Research, a research team from the National Cancer Center Hospital, Tokyo, has investigated the frequency of BRAF V600 mutations in a group of Japanese patients diagnosed with melanoma, determining the relationship between mutations and clinical and pathologic descriptions.
MRV Research
Genetic and Epigenetic Biomarkers in Melanoma Prognosis and Treatment
The incidence of melanoma in the United States has increased over the past 10 years. Although the likelihood of complete regression with treatment approaches 95% in patients with melanoma that has not yet metastasized, patients with metastatic melanoma have a much poorer prognosis. The probability of complete regression drops to approximately 70% in patients with regional metastasis, and may be as low as 20% in patients with distant metastasis.1,2
Skin cancer patients resistant to BRAF-inhibitors studied
Researchers may have found a way to more accurately predict which patients will likely respond to genomic-based follow-up therapies, by looking at unique protein patterns in patients with melanoma.
Radiation plus immunotherapy combo revs up immune system to better attack melanoma, study suggests
Treating metastatic melanoma with a triple threat—including radiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways—could elicit an optimal response in more patients, one that will boost the immune system’s attack on the disease, suggests a new study from a multidisciplinary team of researchers from Penn’s Abramson Cancer Center published today in Nature.